Treatment Updates

published August 5, 2021
Eligible patients can now access Yescarta through Royal Brisbane and Women’s Hospital, Brisbane and the Pete
published March 30, 2021
IMPORTANT Information for all Lymphoma/ CLL Australian patients receiving MabThera® (rituximab)   From
published November 30, 2020
The combination of VENCLEXTA plus obinutuzumab will be available as a fixed duration therapy for previously un

Contact Lymphoma Australia Today!

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Newsletter Sign Up

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.